Altillion

Altillion is a Cambridge-based biotechnology company specializing in the discovery and development of next-generation antibody therapeutics. Founded by industry pioneer John McCafferty, the company utilizes a proprietary mammalian cell display platform that enables the selection of antibodies based on complex functional properties directly within a cellular environment. This technology aims to overcome the limitations of traditional phage display by ensuring better developability and functional relevance of lead candidates. Altillion focuses on high-throughput screening to identify rare antibodies against challenging targets in oncology and immunology. The company's approach integrates advanced molecular biology with large-scale library construction to accelerate the path from discovery to clinical application. By leveraging its unique platform, Altillion partners with other biopharmaceutical firms to solve difficult drug discovery problems.